OpenAI's GPT‑Rosalind
OpenAI launched GPT‑Rosalind, a model targeted at life‑sciences research that the company says is stronger at reasoning in areas like biochemistry and genomics. OpenAI has also released healthcare‑focused tools intended to streamline clinical workflows and reduce administrative burden across health organisations. (reuters.com, ajmc.com)
Biology research often means jumping between papers, gene databases, and lab tools before a single experiment begins. On April 16, OpenAI said GPT‑Rosalind is built to handle more of that work inside one model. (openai.com) OpenAI said GPT‑Rosalind is a life-sciences reasoning model aimed at biochemistry, genomics, drug discovery, and translational medicine, the stage where lab findings are pushed toward patient treatments. Reuters reported the company released it Thursday, April 16, as a research preview. (openai.com, reuters.com) The company said researchers can use the model to search databases, read recent papers, call scientific tools, and propose follow-up experiments. OpenAI is also offering a Life Sciences plugin for Codex that connects to more than 50 scientific tools and data sources. (openai.com, reuters.com) Drug discovery is slow even before clinical trials start: OpenAI said a new drug in the United States typically takes about 10 to 15 years to move from target discovery to regulatory approval. The company’s pitch is that faster literature review, hypothesis generation, and experiment planning could cut time at the front end. (openai.com) OpenAI is releasing GPT‑Rosalind through a “trusted access” program for qualified Enterprise customers in the United States, not as a general public launch. The company said the controls cover eligibility, access management, and organizational governance. (openai.com) OpenAI tied the research model to a broader healthcare push it started on January 8, when it launched OpenAI for Healthcare. That package includes ChatGPT for Healthcare and the OpenAI application programming interface for hospitals, health systems, and developers building clinical software. (openai.com, ajmc.com) OpenAI said ChatGPT for Healthcare is already rolling out at AdventHealth, Baylor Scott & White Health, Boston Children’s Hospital, Cedars-Sinai Medical Center, HCA Healthcare, Memorial Sloan Kettering Cancer Center, Stanford Medicine Children’s Health, and the University of California, San Francisco. AJMC reported the tools are being used for chart summaries, discharge workflows, documentation, and patient education. (openai.com, ajmc.com) The timing lines up with faster adoption inside medicine. The American Medical Association said on March 12 that 81% of physicians now use artificial intelligence in practice, up from 38% in 2023. (ama-assn.org) Drugmakers are also leaning harder on these systems. Reuters said OpenAI is already working with Amgen, Moderna, and Thermo Fisher Scientific on GPT‑Rosalind workflows, and CNBC reported Novo Nordisk announced a separate OpenAI partnership on April 14 to speed drug development. (reuters.com, cnbc.com) OpenAI is trying to sell two versions of the same idea: one model for scientists sorting through biology, and one set of products for clinicians buried in paperwork. For now, both launches are starting in controlled settings, with access limited to qualified organizations rather than open consumer use. (openai.com, openai.com)
